TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21092506

Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 80
Study: 18273539

Group type: EXPERIMENTAL
Intervention: SE stents with low-pressure dilatation <12 atm (n = 143)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Conventional BE stents (n = 136)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: SE stents with low-pressure dilatation <12 atm
Number of subjects: 254

Group type: COMPARATOR
Intervention: Conventional BE stents
Number of subjects: 254
Study: 15842446

Group type: EXPERIMENTAL
Intervention: Early discharge with nurse follow-up (weekly or biweekly telephone calls)
Number of subjects: 101
Study: 12974145

Group type: EXPERIMENTAL
Intervention: Lispro insulin and metformin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Glimepiride and metformin combination
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Two daily doses of biphasic insulin 30/70 with bedtime NPH insulin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Antihyperglycemic metformin and insulin lispro therapy
Number of subjects: 87
Study: 11361162

Group type: EXPERIMENTAL
Intervention: Stapled gastric bypass
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transected gastric bypass
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9183237

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 722

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 722
Study: 1534044

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 or 10 mg/day od)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine s.r. (20 or 40 mg BID)
Number of subjects: 40
Study: 3956558

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of pethidine im
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 mg of extradural pethidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 60 mg of extradural pethidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 30703197

Group type: EXPERIMENTAL
Intervention: Ready-made spectacles
Number of subjects: 460

Group type: COMPARATOR
Intervention: Custom-made spectacles
Number of subjects: 460
Study: 28325070

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26567010

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on days 1 and 8)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Capecitabine (1.25 g/m² orally twice daily on days 1‐14)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Eribulin and Capecitabine
Number of subjects: 1062
Study: 23895319

Group type: EXPERIMENTAL
Intervention: Rate-focused repeated readings (RR) intervention
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prosody-focused repeated readings (RR) intervention
Number of subjects: 76
Study: 21736003

Group type: EXPERIMENTAL
Intervention: Med‐Food Anticancer Program (MFAP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 20137477

Group type: EXPERIMENTAL
Intervention: rhPTH (1-34) 20 microg daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: elcatonin 20 U weekly
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 205
Study: 16703579

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 150 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 225 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg (adolescents)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 150 mg (adolescents)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 225 mg (adolescents)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg (adults)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15571779

Group type: EXPERIMENTAL
Intervention: HPLC method for determination of total pentosidine concentration in plasma
Number of subjects: 0
Study: 11878737

Group type: EXPERIMENTAL
Intervention: PCEA plus night-time infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCEA alone
Number of subjects: 0
Study: 9777544

Group type: EXPERIMENTAL
Intervention: Cervical spine lateral glide oscillatory manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 7828356

Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2893761

Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 1810321

Group type: EXPERIMENTAL
Intervention: Gluma Dentin Bond (two 30‐second applications)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 20
Study: 823586

Group type: EXPERIMENTAL
Intervention: 20 mg chlordiazepoxide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 90
Study: 31281076

Group type: EXPERIMENTAL
Intervention: High-load resistance training (n=14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-load resistance training (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-exercising control (n=16)
Number of subjects: 45
Study: 28801392

Group type: EXPERIMENTAL
Intervention: Care package to increase women's awareness of the need for prompt reporting of RFM and standardized management to identify fetal compromise with timely delivery.
Number of subjects: 0
Study: 26408873

Group type: EXPERIMENTAL
Intervention: Metformin plus glimepiride (3mg once daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Metformin plus gliclazide (80 mg once daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Metformin (500 mg twice daily)
Number of subjects: 180
Study: 23132548

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 794

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Intraoperative conversions to open surgery
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Right colonic cancers
Number of subjects: 794
Study: 21645895

Group type: EXPERIMENTAL
Intervention: drospirenone (DRSP) 2 mg + E(2) 1 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: norethisterone acetate (NETA) 0.5 mg + E(2) 1 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ethinilestradiol (EE) 0.020 mg + DRSP 3 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ethinilestradiol (EE) 0.020 mg + desogestrel 0.15 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (untreated postmenopausal and premenopausal women)
Number of subjects: 90
Study: 19426396

Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg daily
Number of subjects: 429

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study: 16434264

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 15296810

Group type: EXPERIMENTAL
Intervention: Short-duration exclusive breast-feeding with Nevirapine (NVP) and intensive counseling; abrupt cessation of breast-feeding at 4 months.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Intensive and frequent clinic- and home-based counseling to support exclusive breast-feeding.
Number of subjects: 1200
Study: 11305288

Group type: EXPERIMENTAL
Intervention: General health quality of life measure
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: CMV retinitis-specific quality of life measure
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: General health perceptions and energy scales
Number of subjects: 279
Study: 9732194

Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam (2 ml) administered intramuscularly 45 min before ESWL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (2 ml) administered intramuscularly 45 min before ESWL
Number of subjects: 60
Study: 8053882

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of umbilical artery waveform indices in high risk fetuses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler assessment of middle cerebral and aortic vessels in high risk fetuses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of umbilical and uteroplacental vasculatures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umbilical artery waveform indices in low risk fetuses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler waveform indices of middle cerebral and aortic vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 0
Study: 3281462

Group type: EXPERIMENTAL
Intervention: Cefotetan every 12 hours
Number of subjects: 287

Group type: COMPARATOR
Intervention: Cefoxitin every 6 or 8 hours
Number of subjects: 287
Study: 31957953

Group type: EXPERIMENTAL
Intervention: Low-dose TAS-205 (6.67-13.33 mg/kg/dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose TAS-205 (13.33-26.67 mg/kg/dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26253149

Group type: EXPERIMENTAL
Intervention: Organizational, time management, and planning (OTMP) skills training intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 37
Study: 28274234

Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg/day) plus phenylalanine-restricted diet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Phenylalanine-restricted diet only
Number of subjects: 56
Study: 26278126

Group type: EXPERIMENTAL
Intervention: Bilateral truncal ligation (BTL) of the inferior thyroid artery
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-BTL
Number of subjects: 83
Study: 23742620

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 0
Study: 21419010

Group type: COMPARATOR
Intervention: Local anesthetics without buprenorphine (A group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local anesthetics plus 2 µg/kg buprenorphine (B group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular injection 2 µg/kg buprenorphine before anesthesia (C group)
Number of subjects: 60
Study: 18665787

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 6847

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 6847

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 6847

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d (in higher fracture risk subgroup)
Number of subjects: 6847
Study: 17186182

Group type: EXPERIMENTAL
Intervention: lafutidine (10 mg, twice daily for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: famotidine (20 mg, twice daily for 12 weeks)
Number of subjects: 80
Study: 12679422

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (9.6 micro g/kg body weight.d)
Number of subjects: 19
Study: 11592235

Group type: EXPERIMENTAL
Intervention: Subclavicular route
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supraclavicular route
Number of subjects: 100
Study: 9741862

Group type: EXPERIMENTAL
Intervention: Prospective randomized effectiveness studies
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Initial findings from two studies
Number of subjects: 804
Study: 8147520

Group type: EXPERIMENTAL
Intervention: Patient-controlled midazolam sedation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anaesthetist-controlled midazolam sedation
Number of subjects: 30
Study: 3139019

Group type: EXPERIMENTAL
Intervention: Topical mupirocin therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31983237

Group type: EXPERIMENTAL
Intervention: Topical proparacaine 0.5%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical proparacaine 0.5% (additional drop)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Topical proparacaine 0.5% and povidone iodine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient experience surveys
Number of subjects: 36
Study: 30468730

Group type: EXPERIMENTAL
Intervention: PC gaming platform intervention for balance training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group using a computer mouse in standing position
Number of subjects: 54
Study: 27860037

Group type: EXPERIMENTAL
Intervention: Patient-centred communication (PCC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Doctor-centred communication (DCC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient-centred communication with need-orientation (PCC-N)
Number of subjects: 80
Study: 25850462

Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure target (<130 mmHg)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Higher systolic blood pressure target (130-149 mmHg)
Number of subjects: 494
Study: 25000912

Group type: EXPERIMENTAL
Intervention: TAU+CAT
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 30
Study: 22304885

Group type: EXPERIMENTAL
Intervention: Disgust induction (view vomit videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral activation (view waterfall videos)
Number of subjects: 0
Study: 19875482

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 2 mg/d subcutaneously for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 17
Study: 17201013

Group type: EXPERIMENTAL
Intervention: Ultrasound group (n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 41
Study: 15198378

Group type: EXPERIMENTAL
Intervention: Advanced (digital) hearing aids
Number of subjects: 100
Study: 11171825

Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 10%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 20%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 30%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 40%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 10
Study: 9867272

Group type: EXPERIMENTAL
Intervention: Unenhanced CT following oral contrast medium
Number of subjects: 118

Group type: COMPARATOR
Intervention: Barium enema (BE)
Number of subjects: 118
Study: 8561256

Group type: EXPERIMENTAL
Intervention: Control interventions implemented in Mindjil village
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control interventions not implemented (excluded areas)
Number of subjects: 0
Study: 2702970

Group type: EXPERIMENTAL
Intervention: pindolol 15 mg bd + digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: digoxin + verapamil 40 mg tds
Number of subjects: 12
Study: 347034

Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn) at doses of 9 and 12 mg/kg (Lot 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn) at doses of 3-12 mg/kg (Lot 2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (7 patients with herpes zoster)
Number of subjects: 31
Study: 30577404

Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 2228

Group type: COMPARATOR
Intervention: Initial radiation therapy
Number of subjects: 2228
Study: 28895981

Group type: EXPERIMENTAL
Intervention: Monopolar RFT (80°C) for 2 minutes at L2‐3 level
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bipolar RFT (80°C) for 2 minutes at L2‐3 level
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 25894666

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 378

Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 378
Study: 24114738

Group type: EXPERIMENTAL
Intervention: Different opportunity costs of the rare disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different framings of the trade‐off exercises
Number of subjects: 0
Study: 21871372

Group type: EXPERIMENTAL
Intervention: OROS‐MPH + CBT
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 303
Study: 19152543

Group type: EXPERIMENTAL
Intervention: Commonality-focused contact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Difference-focused contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive intergroup contact
Number of subjects: 0
Study: 17497438

Group type: EXPERIMENTAL
Intervention: Azithromycin plus Oral Hygiene Program (OHP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral Hygiene Program (OHP) alone
Number of subjects: 20
Study: 14767720

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11491148

Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide in the morning
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide in the evening
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide (morning or evening)
Number of subjects: 209
Study: 9926056

Group type: EXPERIMENTAL
Intervention: Intensive community service
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard service
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall care-giving activities
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall dissatisfaction with care-giving role
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Patient and illness characteristics
Number of subjects: 124
Study: 9100253

Group type: EXPERIMENTAL
Intervention: Odorant air containing amyl acetate or phenethyl alcohol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Odorless air
Number of subjects: 14
Study: 1743245

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg/d
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7261554

Group type: EXPERIMENTAL
Intervention: NaHCO3 (alkalosis)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: NH4Cl (acidosis)
Number of subjects: 5

Group type: COMPARATOR
Intervention: CaCO3 (control)
Number of subjects: 5
Study: 31467115

Group type: EXPERIMENTAL
Intervention: Inhaled α1-antitrypsin (AAT) 80 mg solution, twice daily for 50 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Inhaled α1-antitrypsin (AAT)
Number of subjects: 168
Study: 28052163

Group type: EXPERIMENTAL
Intervention: Participatory training program
Number of subjects: 918

Group type: COMPARATOR
Intervention: Control group 1 (traditional didactic training)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Control group 2 (traditional didactic training)
Number of subjects: 918
Study: 25403774

Group type: EXPERIMENTAL
Intervention: HeartNetCare -HF™ (HNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 24639423

Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (70 μmol) administered over 5 min immediately before primary percutaneous intervention (PPCI)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo (matching infusion)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 22695223

Group type: EXPERIMENTAL
Intervention: Experiential processing mode during anticipatory processing
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Experiential processing mode during post-event rumination
Number of subjects: 168

Group type: COMPARATOR
Intervention: Analytical processing mode during anticipatory processing
Number of subjects: 168

Group type: COMPARATOR
Intervention: Analytical processing mode during post-event rumination
Number of subjects: 168
Study: 20206784

Group type: EXPERIMENTAL
Intervention: L‐AmB 5 mg/kg per week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (dextrose water)
Number of subjects: 40
Study: 18339112

Group type: EXPERIMENTAL
Intervention: Single tailored intervention (one tailored letter)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Multiple tailored intervention (three tailored letters at intervals of 1 month)
Number of subjects: 508

Group type: COMPARATOR
Intervention: General practitioner letter (control)
Number of subjects: 508
Study: 15982116

Group type: EXPERIMENTAL
Intervention: Ruminating for 25 min
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ruminating for 8-hr
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ruminating
Number of subjects: 3

Group type: COMPARATOR
Intervention: Distracted participants
Number of subjects: 3
Study: 12839661

Group type: EXPERIMENTAL
Intervention: Community intervention including health education for smoking cessation, alcohol consumption restriction, and reinforced treatment for diabetic and hypertensive patients.
Number of subjects: 5309

Group type: COMPARATOR
Intervention: Control cohort (no intervention).
Number of subjects: 5309

Group type: EXPERIMENTAL
Intervention: Community intervention.
Number of subjects: 5309
Study: 10489946

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularisation (TMR)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Continued medication
Number of subjects: 182